EPALINGES, Switzerland, Dec. 1, 2016
EPALINGES, Switzerland, Dec. 1, 2016 /PRNewswire/ -- Mymetics Corporation (OTCQB: MYMX), a pioneer and leader in the research and development of virosome-based vaccines to prevent transmission of human infectious diseases, announced today that its subsidiary Mymetics B.V. has agreed on a research project with Sanofi Pasteur, the vaccine division of Sanofi (NYSE: SNY). The project will investigate the immunogenicity of influenza vaccines based on Mymetics' proprietary virosome technology platform in pre-clinical settings. If this project is successful it could result in a further and more extensive collaboration between the two companies.
"We are very excited to start this initial collaboration project with Sanofi, a world leader in the vaccine industry," said Ronald Kempers, CEO of Mymetics. "We look forward to show that our proprietary virosome technology and more than 30 years of virosome vaccines expertise can make a valuable difference in improving the effectiveness and cost competitiveness of influenza vaccines."
Mymetics Corp. (OTCQB: MYMX) is a Swiss based biotechnology company, with a Research Lab in the Netherlands, focused on the development of next-generation preventative vaccines for infectious diseases. It currently has five vaccines in its pipeline: HIV-1/AIDS, intra-nasal Influenza, Malaria, Chikungunya, Herpes Simplex Virus and the RSV vaccine. HIV, malaria and intra-nasal influenza vaccines have successfully finished Phase 1 clinical trials, while the others are in the pre-clinical phase.
Mymetics' core technology and expertise are in the use of virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane proteins, in combination with rationally designed antigens. Mymetics' vaccines are designed to induce protection against early transmission and infection, focusing on the mucosal immune response as a first-line defense, in combination with humoral and cellular immune responses as a second-line defense, which can be essential for the development of an effective vaccine.
Mymetics' unique approach is being validated through partnerships with leading pharmaceutical or research organizations, including projects with PATH-MVI and the Bill and Melinda Gates Foundation.
For further information, please visit www.mymetics.com.
Forward looking statements
The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements, which are identified by the words "believe," "expect," "anticipate," "intend," "plan" and similar expressions. The statements contained herein which are not based on historical facts are forward-looking statements that involve known and unknown risks and uncertainties that could significantly affect our actual results, performance or achievements in the future and, accordingly, such actual results, performance or achievements may materially differ from those expressed or implied in any forward-looking statements made by or on our behalf. These risks and uncertainties include, but are not limited to, risks associated with our ability to successfully develop and protect our intellectual property, our ability to raise additional capital to fund future operations and compliance with applicable laws and changes in such laws and the administration of such laws. See Mymetics' most recent Form 10-K for a discussion of such risks, uncertainties and other factors. Readers are cautioned not to place undue reliance on these forward- looking statements which speak only as of the date the statements were made.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/mymetics-starts-research-project-with-sanofi-for-influenza-vaccines-300370942.html
SOURCE Mymetics Corporation